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Background: The instant-treatment effect of acupuncture for patients with migraines has been corroborated in
numerous studies. However, most diseases are chronic and tend to recur, so the long-term effect of acupuncture
can verify the existence of sustained efficacy or the placebo effect. Evaluating the efficacy of acupuncture in the
prophylaxis of migraine without aura (MWoA) in China is also important because such studies are lacking.
Methods: This trial is a multicenter, prospective, pragmatic randomized controlled clinical trial. We will randomly
allocate 249 participants to three groups of 83. Patients in the individualized acupoint group will be treated with
individualized acupuncture point prescriptions. The non-acupoint control group will undergo insertion of acupuncture
needles at four bilateral non-points in locations not corresponding to acupuncture points. The waiting-list control
group will not undergo treatment but instead will receive 20 acupuncture treatments for free after a waiting period of
24 weeks. Participants in the individualized acupoint group and non-acupoint control group will receive 20 sessions
over four weeks and then all participants will receive 20 weeks of follow-up.
Discussion: The results of our trial will help to supply evidence for the long-term acupuncture effect for MWoA in a
long follow-up period, and special attention will be paid to comparison with the placebo effect.
Trial registration: The trial was registered at ClinicalTrials.gov (NCT01687660) on 18 September 2012.
Keywords: Study protocol, Pragmatic randomized controlled trial, Acupuncture, Migraine without auraBackground
Migraine is a refractory disorder with high socioeconomic
impact [1-5]. The prevalence of migraine among adults in
the USA is approximately 28.4% [6] and 4.2 to 14.6% in
China [7]. It has been listed as one of the most serious,
chronic, and dysfunctional disorders with a prevalence
equal to quadriplegia, mental disorders, and dementia ac-
cording to the World Health Organization [8]. Several
drugs can be used to reduce the frequency of migraine at-
tacks: aspirin, acetaminophen and NSAIDs [3,9,10]. How-
ever, the success of treatment is usually modest and
tolerability is often suboptimal [11].* Correspondence: acuresearch@126.com
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reproduction in any medium, provided the orAcupuncture is used widely in the prevention and
treatment of migraine. Acupuncture is one of the main
treatments of traditional Chinese medicine (TCM) and
has been used for over 3,000 years. According to time
course of its curative effect, acupuncture effect can be
divided into ‘instant’ and ‘long-term’ effects [12]. In re-
cent years, the instant effect of acupuncture for patients
with migraine has been corroborated by numerous
studies [13-18]. Most diseases are chronic and tend to
recur, so the long-term effect of acupuncture can verify
the existence of sustained efficacy or the placebo effect.
The main factors affecting long-term effects have been
hypothesized to be needling frequency per week and
treatment duration [19].td. This is an open access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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and overseas have paid close attention to how long the
effect is maintained after the last acupuncture session.
Our previous studies on the effect of acupuncture on
migraine showed that participants in the acupuncture
group had fewer days with migraine compared with the
control group during weeks 5 to 8, but that this differ-
ence was not significant. However, a significant reduc-
tion in the number of days with migraine during weeks
13 to 16 was noted [20]. In another clinical trial, patients
were allocated randomly to receive ≤ 12 acupuncture
treatments over three months or to a control interven-
tion offering standard care: headache scores at three
months and 12 months were lower in the acupuncture
group than in controls. Those results suggested that acu-
puncture leads to persistent, clinically relevant benefits
for patients with chronic headache (particularly mi-
graine). That study with long-term follow-up concluded
that the acupuncture effect for migraine prophylaxis can
last nine months after treatment cessation [21].
We conjectured that there would be a long-term cura-
tive effect of acupuncture for migraine without aura
(MWoA) over a longer follow-up period. We have de-
signed a pragmatic trial to investigate the effectiveness
and safety of acupuncture for the prophylaxis of patients
suffering MWoA. In addition, special attention has been
paid to a comparison with the placebo effect, accompan-
ied by observation of the intensity and duration of the
acupuncture effect.
Methods
The design of this study is in accordance with the guide-
lines of the International Headache Society’s (IHS) Com-
mittee on Clinical Trials in Migraine [22].
Design
This randomized, controlled, multicenter pragmatic trial
comprises three parallel groups. It aims to compare the
effectiveness of the individualized acupoint group, non-
acupoint control group (in locations not corresponding
to acupuncture points), and the waiting-list control
group (who receive delayed active acupuncture treat-
ment 24 weeks later) (Figure 1).
In all groups, participants will not take any regular
medications for migraines, but will be permitted to use
necessary analgesics such as the triptans, ergotamines
and analgesics during acute attacks of migraine. The
type, dose and time of administration of the agent must
be recorded in a headache diary.
The central randomization will be conducted using
the Brightech-Magnasoft Clinical Information Manage-
ment System (CIMS) (Address: 285 Davidson Avenue,
Suite 504, Somerset, NJ 08873, Phone: 908-790-8888,
Web Site: http://www.brightech-intl.com). Allocation totreatment groups uses a stratified block dynamic ran-
domization method with permuted block, which is
automatically under the control of a central computer
system. To guarantee allocation concealment, rando-
mization will be done by an independent researcher.
The website and mobile message will be used to send
randomization information (including the partici-
pants’ name in pinyin format, sex and date of birth)
to the CIMS center. An independent assessor will
interview the participants and carry out the screening.
Random numbers and group assignment will be con-
firmed immediately through Email or short message
service (SMS) to the independent assessor. This pro-
cedure guarantees that randomization concealment is
adequate, and not influenced by the acupuncturists or
participants. Participants allocated to individualized
acupoint or non-acupoint groups will be blinded to
their treatment allocation. However, blinding is clearly
not possible in the waiting-list control group. We
shall endeavor to ensure that participants begin the
RCT with the same expectations of effectiveness by
informing them that the treatments provided are ef-
fective. All participants will be assessed and the re-
sults will be analyzed by professionals blinded to the
allocations of the different treatments. The duration
of the study for every participant will be 28 weeks.
Four of them will be before randomization (baseline),
followed by four weeks of treatment, and finally
20 weeks of follow-up.
The Consolidated Standards of Reporting Trials
(CONSORT) statement [23] (http://www.consort-state-
ment.org/home/) has been used as a framework for
developing the study methodology. The protocol of this
study was approved by the Ethics Committee of the
Teaching Hospital of Chengdu University of TCM
(Chengdu, China) in June 2012 and is in accordance with
the Declaration of Helsinki. The trial protocol has permis-
sion number 2012KL-007. The trial was registered in Clini-
calTrials.gov with approval number NCT01687660. All
participants have provided written informed consent to be
included in the trial.
Setting and participants
A total of 249 participants meeting the diagnostic cri-
teria for MWoA according to the second edition of the
IHS’ International Classification of Headache Disorders
(ICHD-II, IHS 2004) will be recruited at three centers
(Chengdu, Hunan and Chongqing) [24]. Participants will
be: informed (verbally and through a print-out) of the
possible risks associated with the study; instructed to
complete the headache diary; told that they can with-
draw from the trial at any time without specifying rea-
sons; and told that they can voluntarily provide written
informed consent before enrollment.
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Figure 1 Trial profile. Participants with a diagnosis of migraine without aura will be recruited at three centers (enrollment areas of Chengdu,
Hunan and Chongqing) taking part in the study. All participants should endure a baseline period of four weeks and inappropriate participants
will be excluded. A total of 249 participants will be randomized to three groups: individualized acupoint, non-acupoint control, and waiting-list
control. Each patient will receive four weeks of treatment and 20 weeks of follow-up. Outcome will be measured before randomization, the week
of the last acupuncture session, and 8, 12, 16, 20 and 24 weeks after randomization, except that the acupuncture expectation value will be
assessed before randomization, and MSQ, SAS and SDS will be assessed only at four weeks after treatment.
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Eligible participants should match the diagnostic criteria
for MWoA set by ICHD-II [24]. They must: (i) be male
or female, aged between 18 and 65 years, with initial on-
set of migraines before the age of 50 years; (ii) have had
two to eight migraine attacks, but less than fifteen days
of attacks per month during the previous three months
and during baseline measurement; (iii) suffering from
acute migraine attack for ≥ one year; (iv) have completed
the headache diary and given baseline values within it;(v) provided written informed consent by themselves or
their next of kin.
Exclusion criteria
Participants with any of the following conditions will be ex-
cluded: (i) headache caused by organic disorders such as
subarachnoid hemorrhage, cerebral hemorrhage, cerebral
embolism, cerebral thrombosis, vascular malformation, ar-
teritis, hypertension or arteriosclerosis; (ii) neurological di-
seases, immunodeficiency, bleeding disorders and allergies.
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vious month, pregnant women, women in lactation,
and those planning to become pregnant within the
next six months, and those involved in other RCTs,
will also be excluded.
Interventions
Treatment strategies were developed by consensus with
experienced acupuncture practitioners and a neurologist.
Based on TCM theory, a systematic review of the li-
terature revealed that acupoints on the Shaoyang merid-
ian were the ones chiefly selected for migraine [19]. There
are three groups in this trial: individualized acupoint
group, non-acupoint control group, and waiting-list con-
trol group. The location and manipulations of individual-
ized acupoints and non-acupoints are shown in Table 1.
Individualized acupoint group
In the individualized acupoint group, the acupoint pre-
scriptions used will be personalized to each participant
and at the discretion of the acupuncturist. Differentiating
the location of meridians is an important part of TCM
theory, so it was used to select acupoints on the basis of
the evolution of the patient’s symptoms. Fengchi (GB20)Table 1 Details of the acupoint and non-acupoint groups
Group Acupoint












(i) At the medial arm on the anterior border of th
deltoid muscle at the junction of deltoid and bice
(ii) Half way between the tip of the elbow and ax
(iii) Ulnar side, half way between the epicondylus
and ulnar side of the wrist
(iv) Edge of the tibia 1 to 2 cm lateral to the Zusa
The individualized acupoint group Fengchi (GB20) and Shuaigu (GB8) are obligatory
and GB8 horizontally 0.5 to 0.8 cm. Additional points can be chosen according to s
attacks the temporal side): Waiguan (SJ5) and Yanglingquan (GB34); SJ5 should be p
(ii) Taiyang headache (headache involving the occiput): Kunlun (BL 60) and Houxi (S
perpendicularly 0.5 to 0.8 cm; (iii) Yangming headache (headache involving the fore
perpendicularly 0.5 to 1 cm and ST44 perpendicularly 0.5 to 1 cm; (iv) Jueyin heada
intended to be punctured perpendicularly 0.5 to 1 cm and GB40 perpendicularly 0.
In the non-acupoint control group, the four non-points are: (i) at the medial arm on
deltoid and biceps muscles; (ii) half way between the tip of the elbow and the axill
and ulnar side of the wrist; (iv) The edge of the tibia 1 to 2 cm lateral to the Zusanl
dicularly 0.5 to 1 cm.and Shuaigu (GB8), having the highest frequency, were se-
lected as obligatory acupoints. Additional points, which
were used in a previous study [25], could be chosen ac-
cording to syndrome differentiation of meridians: (i) Shao-
yang headache (headache only attacks the temporal side):
Waiguan (SJ5) and Yanglingquan (GB34); (ii) Taiyang
headache (headache involves the occiput): Kunlun (BL 60)
and Houxi (SI3); (iii) Yangming headache (headache in-
volves the forehead): Hegu (LI4) and Neiting (ST44); (iv)
Jueyin headache (headache involves the vertex): Taichong
(LR3) and Qiuxu (GB40).
The acupuncturist responsible for the treatment will
insert sterile, single-use filiform acupuncture needles
(length, 25 to 40 mm; diameter, 0.25 mm) and auxiliary
acupuncture needles (without manipulating the needles)
of length 13 mm and diameter 0.18 mm after first disin-
fecting the skin with the participant lying down. The nee-
dles used are Hwato needles (Suzhou, China). The
puncture will be made according to TCM standards to a
depth of 0.3 to 1 cm depending on the points selected. In-
sertion will be followed by the stimulation methods of lift-
ing and thrusting combined with twirling and rotating the
needles to produce a sensation known as Deqi. Acupoints
on the left and right side are employed alternatively, andManipulation
(i) is punctured obliquely 0.8 to 1.2 cm
toward to apex nasi
(ii) is punctured horizontally 0.5 to 0.8 cm
(iii) is punctured perpendicularly 0.5 to 1 cm
(iv) is punctured perpendicularly 1 to 1.5 cm
(v) is punctured perpendicularly 0.5 to 0.8 cm
(vi) is punctured perpendicularly 0.5 to 0.8 cm
(vii) is punctured perpendicularly 0.5 to 1 cm
(viii) is punctured perpendicularly 0.5 to 1 cm
(ix) is punctured perpendicularly 0.5 to 1 cm
(x) is punctured perpendicularly 0.5 to 0.8 cm
e insertion of the
ps muscles
(i) is punctured perpendicularly 0.5 to 1 cm
illae (ii) is punctured perpendicularly 0.5 to 1 cm
medialis of the humerus (iii) is punctured perpendicularly 0.5 to 1 cm
nli (ST36) horizontally (iv) is punctured perpendicularly 0.5 to 1 cm
acupoints. GB20 will be punctured obliquely 0.8 to 1.2 cm toward apex nasi
yndrome differentiation of meridians: (i) Shaoyang headache (headache only
unctured perpendicularly 0.5 to 1 cm and GB34 perpendicularly 1 to 1.5 cm;
I3); BL60 will be punctured perpendicularly 0.5 to 0.8 cm and SI3
head): Hegu (LI4) and Neiting (ST44); LI4 is about to be punctured
che (headache involving the vertex): Taichong (LR3) and Qiuxu (GB40), LR3 is
5 to 0.8 cm.
the anterior border of the insertion of the deltoid muscle at the junction of
ae; (iii) ulnar side, half way between the epicondylus medialis of the humerus
i (ST36) horizontally. All of the four non-points ought to be punctured perpen-
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will be punctured 2 mm lateral to each acupoint to a depth
of 2 mm without manual stimulation. This method has
been used successfully in our previous study [20,26]. Han’s
acupoint nerve stimulator (HANS; model LH 200A; TENS,
Nanjing, China) will be connected after needle insertion.
Participants in this group will receive 20 sessions over
a four-week period. Each session will be administered
once a day for five continuous days followed by a two-
day rest interval, and the participant will be connected
to the stimulator for 30 minutes. All patients should
complete ≥ ten treatment sessions. The stimulation fre-
quency will be 2/100 Hz, and intensity varied from 0.1
to 1.0 mA until the participants feel comfortable. Nee-
dles will be retained in situ for 30 minutes and then the
acupoint holes covered with clean cotton balls to avoid
bleeding upon needle withdrawal.
Non-acupoint control acupuncture
Participants assigned randomly to this group will be
given non-acupoint acupuncture, i.e., insertion of acu-
puncture needles at four bilateral non-points. The proto-
col of non-acupoints was developed in our latest
acupuncture clinical trial [27]. The method will not dif-
fer from that used for the individualized acupoint group
except for that an attempt will not be made to yield the
Deqi sensation.
Waiting-list control group
No intervention will be used in the waiting-list group.
The participants will be informed that they are sched-
uled to receive 20 acupuncture treatments for free after
a waiting period of 24 weeks.
Outcome measurement
The efficacy of acupuncture for migraine is assessed by the
primary outcome measure: change in the frequency of mi-
graine attacks during the 16th week after randomization.
The secondary outcome measures are: (i) frequency of
migraine attacks; (ii) number of days with migraine; (iii)
visual analog scale (VAS) score and grade of headache in-
tensity (0 to 3); (iv) mean duration of migraine attack; (v)
medication intake; (vi) number of participants with ad-
verse events (AEs) and serious adverse events (SAEs); (vii)
summary scales of the Migraine-Specific Quality-of-Life
Questionnaire (MSQ) [20], Zung Self-Rating Anxiety
Scale (SAS) [28] and Zung Self-rating Depression Scale
(SDS) [28]; and (viii) acupuncture expectation value.
The outcome measures shown above will be measured
before randomization, the week of the last acupuncture ses-
sion, and 8, 12, 16, 20 and 24 weeks after randomization,
except that the acupuncture expectation value is assessed
before randomization, and MSQ, SAS and SDS are as-
sessed only at four weeks after treatment.Any AE and SAE, and how they are dealt with, will be
recorded during the four treatment weeks and 20
follow-up weeks. AEs include bleeding, hematoma, faint-
ing, severe pain, and local infection. Any SAE (including
life-threatening SAEs) can lead to hospitalization or pro-
longation of existing hospitalization, and persistent or
significant disability/incapacity. Therefore, intervention
to prevent permanent impairment is required. If partici-
pants suffer AEs or SAEs, all details will be documented.
All physicians who enroll participants and assessors
who collect data must attend training classes to ensure
all practices at each hospital are identical. The training
classes comprise theoretical and practical lessons. Physi-
cians must pass the training test to understand the pur-
pose and content of the trial, treatment strategies and
quality control. Additionally, to maintain quality control,
quality monitoring will be carried out by Brightech-
Magnasoft CIMS, and specially trained physicians will
check all trial processes. Detailed time points of out-
come assessments are provided in Table 2.
Calculation of sample size and statistical analyses
Sample size will be estimated by NQuery Advisor v4.0
(Statistical Solutions, Boston, MA, USA). For this trial, it
has been determined prospectively that α = 0.05 and 1-β =
0.90, and that the standard deviation will be 1.81 according
to the three group subsets. According to a previous study
[20], we anticipated that a mean frequency of migraine at-
tacks in the non-acupoint group is 3.7 whereas, in the indi-
vidualized acupoint group, it is 2.7. Hence, a minimum
difference of clinical effect is 1.0. Thus, ≥ 70 participants
are required for each group. To compensate for a preva-
lence of withdrawal of 15%, we plan to enroll 249 partici-
pants in the three groups, with 83 patients for each group.
For the final outcome analysis, we will make all pair-
wise comparisons using a general linear model adjusted
for baseline value, age, sex, clinical center, and disease
course. The comparison between the individualized acu-
point group and non-acupoint group is the primary
interest in this study. In general, the summarization of
difference is in accordance with CONSORT expecta-
tions, which will be addressed using effect size estimates
and the associated confidence intervals.
All data in this trial will be assessed by Brightech-
Magnasoft CIMS, with SPSS v13.0 (SPSS, Chicago, IL,
USA) and SAS v9.1.3 (SAS, Cary, NC, USA). All ana-
lyses will be done on the intention-to-treat (ITT) popu-
lation (that is, any participant randomized regardless of
whether he/she receives any treatment). Missing data
will be replaced according to the principle of multiple
imputation. In addition, the per protocol (PP) popu-
lation will be analyzed. The results of ITT and PP ana-
lyses will be compared to ascertain if the results are
consistent. Moreover, analysis of variance (ANOVA) for
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Vital signs × × × × × × ×
Change of medical history × × × × × × ×
Random allocation ×
Acupuncture ⊗
Headache diary × × × × × × ×
Visual analog scale × × × × × × ×














The detailed outcome assessment time points are provided. The outcome
measures will be measured at baseline, the week of the last acupuncture
session, and 8, 12, 16, 20 and 24 weeks after randomization, except that the
acupuncture expectation value is assessed before randomization, and that
MSQ, SAS and SDS are assessed only at four weeks after treatment.
× = all groups; ⊗ = treatment groups.
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The Chi-square test will be used for categorical vari-
ables. P < 0.05 will be considered significant.
Discussion
Pragmatic and explanatory randomized controlled trials
play a significant part in the evaluation of healthcare in-
terventions in China and overseas [29]. Explanatory tri-
als are designed to ascertain whether a treatment has
efficacy under ideal experimental conditions. Pragmatic
trials are used to discover how effective a treatment is in
routine everyday practice, with the aim of providing evi-
dence that will help policymakers, practitioners or pa-
tients make choices between two interventions [30].
Pragmatic trials are used to ascertain if a treatment is
beneficial under conditions close to those that operate in
routine care, whereas effectiveness studies adopt a more
pragmatic approach [31,32]. The greatest strength ofpragmatic trials is that they can deliver evidence of ef-
fectiveness in the causal effects of a treatment [33].
The results of several trials suggest that an enhanced
placebo effect impacts the acupuncture effect, which
may explain patients’ positive beliefs and expectations of
benefit of acupuncture and a benign acupuncturist-
patient relationship [18,34-38]. We believe that this trial
will demonstrate that the acupuncture effect is not due
primarily to the physiological effects of acupoints. These
influential factors have been standardized as strictly as
possible and the selection of non-acupoints is different
from those in previous studies. However, we cannot rule
out the possibility that intervention using non-acupoint
acupuncture may have some physiological effects. We
designed a waiting-list group to ascertain if a psycho-
logical effect exists. There is no therapeutic intervention
in the waiting-list group. Hence, we anticipate that the
placebo effect from the acupuncturist-patient relation-
ship and patients’ expectancy of benefit of acupuncture
may be zero compared with the non-acupoint group.
Furthermore, using parameters to attest to the specificity
of acupoints, we will use non-acupoint stimulation in
the control group. All participants will be followed-up.
The strength of our trial is strict central randomization,
which will ensure adequate concealment of allocation and
an equal chance of assignment in each group at all centers.
Successful data collection from headache diaries and flexi-
bility in treatment prescription will improve the compliance
of practitioners. However, our trial will be limited by our
inability to prevent patients knowing whether they are re-
ceiving treatment or waiting-list treatment. This factor may
cause a high dropout rate in the waiting-list group because
patients expect to receive acupuncture treatment when
they join the trial. To prevent the expected high dropout
rate, patients in the waiting-list group will receive 20 ses-
sions of free acupuncture treatment after the entire course.
Briefly, the purpose of this trial is not to evaluate the
efficacy of acupuncture as a painkiller, but to evaluate
the duration and intensity of the effectiveness of acu-
puncture for the prophylaxis of MWoA in daily clinical
practice in China.Trial status
This study is currently recruiting patients. This proce-
dure started on 15 October 2012. This trial is anticipated
to be completed on 15 September 2014.
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